ORPH

IntroductionAn international biotech company, headquartered in the EU approached hVIVO to explore the possibility of performing a RSV Phase IIa challenge study. The investigational product was a novel recombinant modified

Candidate exhibits a novel mechanism of action and differs considerably from previously approved drugs Open Orphan – a specialists in testing infectious and respiratory disease products using human challenge clinical

A growing specialist contract organization, hVIVO—a subsidiary of Open Orphan plc—has been tapped by Cocrystal Pharma to conduct a phase 2a clinical trial of its novel broad-spectrum, orally administered antiviral

Gene therapy offers significant potential to treat diseases with high unmet medical need. However, the unique nature of these therapies poses challenges in product development, namely: safety concerns, efficacy issues, or

FluCamp is all about improving the health of the population, through increasing understanding around common viral illnesses. Ultimately, the more that we understand about how viruses affect the human immune

In the early months of the pandemic, human challenge clinical trials drew amplified public interest on its potential to accelerate the hunt for Covid-19 vaccines. Fast forward two years later, while

Allergic rhinitis or, as it is commonly known, hay fever, is a reaction to allergens in the air. Most commonly this is a reaction to the pollen count, but can

In your 20’s life tends to change dramatically – and it can be easy to let your health take a back seat. However, it is a period in which is

For 20+ years, members of the CMC (Chemistry Manufacturing and Control) team have supported and are supporting numerous pharmaceutical companies to ensure the timely development and manufacture of high-quality drug